1
|
Vazquez T, Patel J, Kodali N, Diaz D, Bashir MM, Chin F, Keyes E, Sharma M, Sprow G, Grinnell M, Dan J, Werth VP. Plasmacytoid Dendritic Cells Are Not Major Producers of Type 1 IFN in Cutaneous Lupus: An In-Depth Immunoprofile of Subacute and Discoid Lupus. J Invest Dermatol 2023:S0022-202X(23)03126-3. [PMID: 38086428 DOI: 10.1016/j.jid.2023.10.039] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2023] [Revised: 10/16/2023] [Accepted: 10/25/2023] [Indexed: 03/12/2024]
Abstract
The immunologic drivers of cutaneous lupus erythematosus (CLE) and its clinical subtypes remain poorly understood. We sought to characterize the immune landscape of discoid lupus erythematosus and subacute CLE using multiplexed immunophenotyping. We found no significant differences in immune cell percentages between discoid lupus erythematosus and subacute CLE (P > .05) with the exception of an increase in TBK1 in discoid lupus erythematosus (P < .05). Unbiased clustering grouped subjects into 2 major clusters without respect to clinical subtype. Subjects with a history of smoking had increased percentages of neutrophils, disease activity, and endothelial granzyme B compared with nonsmokers. Despite previous assumptions, plasmacytoid dendritic cells (pDCs) did not stain for IFN-1. Skin-eluted and circulating pDCs from subjects with CLE expressed significantly less IFNα than healthy control pDCs upon toll-like receptor 7 stimulation ex vivo (P < .0001). These data suggest that discoid lupus erythematosus and subacute CLE have similar immune microenvironments in a multiplexed investigation. Our aggregated analysis of CLE revealed that smoking may modulate disease activity in CLE through neutrophils and endothelial granzyme B. Notably, our data suggest that pDCs are not the major producers of IFN-1 in CLE. Future in vitro studies to investigate the role of pDCs in CLE are needed.
Collapse
Affiliation(s)
- Thomas Vazquez
- Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania, USA; Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA
| | - Jay Patel
- Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania, USA; Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA
| | - Nilesh Kodali
- Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania, USA; Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA
| | - DeAnna Diaz
- Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania, USA; Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA
| | - Muhammad M Bashir
- Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania, USA; Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA
| | - Felix Chin
- Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania, USA; Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA
| | - Emily Keyes
- Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania, USA; Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA
| | - Meena Sharma
- Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania, USA; Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA
| | - Grant Sprow
- Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania, USA; Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA
| | - Madison Grinnell
- Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania, USA; Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA
| | - Joshua Dan
- Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania, USA; Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA
| | - Victoria P Werth
- Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania, USA; Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
| |
Collapse
|
2
|
Chen HW, Sprow G, Feng R, Werth VP, Chong BF. Cigarette smoking is associated with decreased long-term treatment cessation of mycophenolate mofetil and methotrexate in cutaneous lupus erythematosus. Lupus 2023; 32:1134-1137. [PMID: 37328162 PMCID: PMC10527208 DOI: 10.1177/09612033231183500] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/18/2023]
Affiliation(s)
- Henry W. Chen
- University of Texas Southwestern Medical Center, Department of Dermatology, Dallas, TX
| | - Grant Sprow
- University of Pennsylvania, Department of Dermatology, Philadelphia, PA
- Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA
| | - Rui Feng
- University of Pennsylvania, Department of Biostatistics, Philadelphia, PA
| | - Victoria P. Werth
- University of Pennsylvania, Department of Dermatology, Philadelphia, PA
- Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA
| | - Benjamin F. Chong
- University of Texas Southwestern Medical Center, Department of Dermatology, Dallas, TX
| |
Collapse
|
3
|
Dan J, Sprow G, Diaz D, Kodali N, Patel J, Vazquez T, Werth VP. Bullous pemphigoid: Comparing the prevalence and severity of itch and pain. J Am Acad Dermatol 2023; 89:159-160. [PMID: 36842504 DOI: 10.1016/j.jaad.2023.02.025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2022] [Revised: 02/17/2023] [Accepted: 02/21/2023] [Indexed: 02/28/2023]
Affiliation(s)
- Joshua Dan
- Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Corporal Michael J. Crescenz Veteran Affairs Medical Center, Philadelphia, Pennsylvania
| | - Grant Sprow
- Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Corporal Michael J. Crescenz Veteran Affairs Medical Center, Philadelphia, Pennsylvania
| | - DeAnna Diaz
- Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Corporal Michael J. Crescenz Veteran Affairs Medical Center, Philadelphia, Pennsylvania
| | - Nilesh Kodali
- Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Corporal Michael J. Crescenz Veteran Affairs Medical Center, Philadelphia, Pennsylvania
| | - Jay Patel
- Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Corporal Michael J. Crescenz Veteran Affairs Medical Center, Philadelphia, Pennsylvania
| | - Thomas Vazquez
- Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Corporal Michael J. Crescenz Veteran Affairs Medical Center, Philadelphia, Pennsylvania
| | - Victoria P Werth
- Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Corporal Michael J. Crescenz Veteran Affairs Medical Center, Philadelphia, Pennsylvania.
| |
Collapse
|
4
|
Dan J, Sprow G, Concha J, Patel J, Kodali N, Diaz D, Vazquez T, Werth VP. A comparison of the efficacy of Skindex-16 and Skindex-29 in dermatomyositis. Br J Dermatol 2023:7153252. [PMID: 37146088 DOI: 10.1093/bjd/ljad133] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2022] [Revised: 03/15/2023] [Accepted: 04/25/2023] [Indexed: 05/07/2023]
Abstract
Recently, more emphasis has been placed on patient-reported outcomes in clinical trials, which has inadvertently led to an increase in respondent burden. In this investigation, we found that the Skindex-16 form captures patient-reported quality of life in dermatomyositis as well as the Skindex-29 form, but with fewer questions. Additional questions regarding photosensitivity, body image, and cosmetic use did not correlate with skin activity in dermatomyositis.
Collapse
Affiliation(s)
- Joshua Dan
- Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
- Corporal Micheal J. Crescenz Veterans Affairs Medical Center, Philadelphia, PA, USA
| | - Grant Sprow
- Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
- Corporal Micheal J. Crescenz Veterans Affairs Medical Center, Philadelphia, PA, USA
| | - Josef Concha
- Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
- Corporal Micheal J. Crescenz Veterans Affairs Medical Center, Philadelphia, PA, USA
| | - Jay Patel
- Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
- Corporal Micheal J. Crescenz Veterans Affairs Medical Center, Philadelphia, PA, USA
| | - Nilesh Kodali
- Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
- Corporal Micheal J. Crescenz Veterans Affairs Medical Center, Philadelphia, PA, USA
| | - DeAnna Diaz
- Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
- Corporal Micheal J. Crescenz Veterans Affairs Medical Center, Philadelphia, PA, USA
| | - Thomas Vazquez
- Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
- Corporal Micheal J. Crescenz Veterans Affairs Medical Center, Philadelphia, PA, USA
| | - Victoria P Werth
- Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
- Corporal Micheal J. Crescenz Veterans Affairs Medical Center, Philadelphia, PA, USA
| |
Collapse
|
5
|
Sprow G, Toker M, Khanna U, Wu B. Distinguishing monkeypox from its mimickers. J Med Virol 2023; 95:e28523. [PMID: 36695517 DOI: 10.1002/jmv.28523] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2022] [Revised: 12/11/2022] [Accepted: 01/22/2023] [Indexed: 01/26/2023]
Affiliation(s)
- Grant Sprow
- Division of Dermatology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York, USA
| | - Michelle Toker
- Division of Dermatology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York, USA
| | - Urmi Khanna
- Division of Dermatology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York, USA
| | - Benedict Wu
- Division of Dermatology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York, USA
| |
Collapse
|
6
|
Dan J, Afarideh M, Sprow G, Keyes E, Diaz D, Vazquez T, Kodali N, Werth VP. Preliminary definition of cutaneous flare in dermatomyositis: A retrospective review. J Am Acad Dermatol 2023; 88:190-191. [PMID: 35381299 PMCID: PMC9526755 DOI: 10.1016/j.jaad.2022.03.054] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2021] [Revised: 03/21/2022] [Accepted: 03/28/2022] [Indexed: 12/24/2022]
Affiliation(s)
- Joshua Dan
- Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, and the Corporal Michael J. Crescenz Veteran Affairs Medical Center, Philadelphia, Pennsylvania
| | - Mohsen Afarideh
- Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, and the Corporal Michael J. Crescenz Veteran Affairs Medical Center, Philadelphia, Pennsylvania
| | - Grant Sprow
- Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, and the Corporal Michael J. Crescenz Veteran Affairs Medical Center, Philadelphia, Pennsylvania
| | - Emily Keyes
- Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, and the Corporal Michael J. Crescenz Veteran Affairs Medical Center, Philadelphia, Pennsylvania
| | - DeAnna Diaz
- Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, and the Corporal Michael J. Crescenz Veteran Affairs Medical Center, Philadelphia, Pennsylvania
| | - Thomas Vazquez
- Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, and the Corporal Michael J. Crescenz Veteran Affairs Medical Center, Philadelphia, Pennsylvania
| | - Nilesh Kodali
- Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, and the Corporal Michael J. Crescenz Veteran Affairs Medical Center, Philadelphia, Pennsylvania
| | - Victoria P Werth
- Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, and the Corporal Michael J. Crescenz Veteran Affairs Medical Center, Philadelphia, Pennsylvania.
| |
Collapse
|
7
|
Abstract
The majority of patients with systemic lupus erythematosus (SLE) have cutaneous manifestations at some point in their disease course. The skin findings in SLE are classified as SLE-specific or SLE-nonspecific based on histopathologic findings. SLE-specific skin diseases include chronic cutaneous lupus erythematosus (CLE), subacute CLE, and acute CLE. There are subsets of skin lesions within each group and the likelihood of associated SLE varies among them. SLE-nonspecific lesions are more common in patients with SLE and tend to coincide with active systemic disease. SLE-nonspecific lesions may be seen as a feature of another disease process, including other connective tissue diseases. It is important for the rheumatologist to be familiar with the spectrum of cutaneous diseases in SLE to help prognosticate the likelihood of systemic disease and to ensure patients receive timely dermatologic care with the goal of controlling disease activity to prevent damage.
Collapse
Affiliation(s)
- Courtney Stull
- C. Stull, MD, Corporal Michael J. Crescenz VAMC, and Department of Dermatology, University of Pennsylvania, Philadelphia, and Department of Rheumatology, University of Pittsburgh Medical Center, Pittsburgh
| | - Grant Sprow
- G. Sprow, BA, V.P. Werth, MD, Corporal Michael J. Crescenz VAMC, and Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - Victoria P Werth
- G. Sprow, BA, V.P. Werth, MD, Corporal Michael J. Crescenz VAMC, and Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
| |
Collapse
|
8
|
Sprow G, Dan J, Feng R, Werth VP. Comparing dermatologic patient-reported outcome measures in cutaneous lupus erythematosus. Lupus Sci Med 2022; 9:9/1/e000827. [PMID: 36521938 PMCID: PMC9756276 DOI: 10.1136/lupus-2022-000827] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2022] [Accepted: 12/06/2022] [Indexed: 12/23/2022]
Affiliation(s)
- Grant Sprow
- Dermatology, Corporal Michael J Crescenz VA Medical Center, Philadelphia, Pennsylvania, USA,Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA
| | - Joshua Dan
- Dermatology, Corporal Michael J Crescenz VA Medical Center, Philadelphia, Pennsylvania, USA,Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA
| | - Rui Feng
- Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - Victoria P Werth
- Dermatology, Corporal Michael J Crescenz VA Medical Center, Philadelphia, Pennsylvania, USA,Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA
| |
Collapse
|
9
|
Waxer J, Wong K, Modiri A, Charpentier A, Moiseenko V, Ronckers C, Taddei P, Constine L, Sprow G, Tamrazi B, MacDonald S, Olch A. Risk of Cerebrovascular Events among Childhood and Adolescent Patients Receiving Cranial Radiotherapy: A PENTEC Normal Tissue Outcomes Comprehensive Review. Int J Radiat Oncol Biol Phys 2022. [DOI: 10.1016/j.ijrobp.2022.07.1758] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
10
|
Waxer JF, Wong K, Modiri A, Charpentier AM, Moiseenko V, Ronckers CM, Taddei PJ, Constine LS, Sprow G, Tamrazi B, MacDonald S, Olch AJ. Risk of Cerebrovascular Events Among Childhood and Adolescent Patients Receiving Cranial Radiation Therapy: A Pediatric Normal Tissue Effects in the Clinic Normal Tissue Outcomes Comprehensive Review. Int J Radiat Oncol Biol Phys 2022:S0360-3016(22)00643-5. [PMID: 36057476 DOI: 10.1016/j.ijrobp.2022.06.079] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2022] [Revised: 05/19/2022] [Accepted: 06/21/2022] [Indexed: 10/14/2022]
Abstract
PURPOSE Radiation-induced cerebrovascular toxicity is a well-documented sequelae that can be both life-altering and potentially fatal. We performed a meta-analysis of the relevant literature to create practical models for predicting the risk of cerebral vasculopathy after cranial irradiation. METHODS AND MATERIALS A literature search was performed for studies reporting pediatric radiation therapy (RT) associated cerebral vasculopathy. When available, we used individual patient RT doses delivered to the Circle of Willis (CW) or optic chiasm (as a surrogate), as reported or digitized from original publications, to formulate a dose-response. A logistic fit and a Normal Tissue Complication Probability (NTCP) model was developed to predict future risk of cerebrovascular toxicity and stroke, respectively. This NTCP risk was assessed as a function of prescribed dose. RESULTS The search identified 766 abstracts, 5 of which were used for modeling. We identified 101 of 3989 pediatric patients who experienced at least one cerebrovascular toxicity: transient ischemic attack, stroke, moyamoya, or arteriopathy. For a range of shorter follow-ups, as specified in the original publications (approximate attained ages of 17 years), our logistic fit model predicted the incidence of any cerebrovascular toxicity as a function of dose to the CW, or surrogate structure: 0.2% at 30 Gy, 1.3% at 45 Gy, and 4.4% at 54 Gy. At an attained age of 35 years, our NTCP model predicted a stroke incidence of 0.9% to 1.3%, 1.8% to 2.7%, and 2.8% to 4.1%, respectively at prescribed doses of 30 Gy, 45 Gy, and 54 Gy (compared with a baseline risk of 0.2%-0.3%). At an attained age of 45 years, the predicted incidence of stroke was 2.1% to 4.2%, 4.5% to 8.6%, and 6.7% to 13.0%, respectively at prescribed doses of 30 Gy, 45 Gy, and 54 Gy (compared with a baseline risk of 0.5%-1.0%). CONCLUSIONS Risk of cerebrovascular toxicity continues to increase with longer follow-up. NTCP stroke predictions are very sensitive to model variables (baseline stroke risk and proportional stroke hazard), both of which found in the literature may be systematically erring on minimization of true risk. We hope this information will assist practitioners in counseling, screening, surveilling, and facilitating risk reduction of RT-related cerebrovascular late effects in this highly sensitive population.
Collapse
Affiliation(s)
- Jonathan F Waxer
- Department of Radiation Oncology, Southern California Permanente Medical Group, Los Angeles, California
| | - Kenneth Wong
- Radiation Oncology Program, Children's Hospital Los Angeles/Keck School of Medicine of the University of Southern California, Los Angeles, California.
| | - Arezoo Modiri
- Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, Maryland
| | - Anne-Marie Charpentier
- Department of Radiation Oncology, Center Hospitalier de l'Universite de Montreal, Montreal, QC, Canada
| | - Vitali Moiseenko
- Department of Radiation Medicine and Applied Science, University of California San Diego, San Diego, California
| | - Cécile M Ronckers
- Department of Pediatric Oncology, Princess Maxima Center for Pediatric Oncology, Utretcht, Netherlands
| | - Phillip J Taddei
- Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota; Department of Radiation Oncology, University of Washington School of Medicine, Seattle, Washington
| | - Louis S Constine
- Department of Radiation Oncology and Pediatrics, University of Rochester Medical Center, Rochester, New York
| | - Grant Sprow
- Albert Einstein College of Medicine, Bronx, New York
| | - Benita Tamrazi
- Department of Radiology, Children's Hospital Los Angeles/Keck School of Medicine of the University of Southern California, Los Angeles, California
| | - Shannon MacDonald
- Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
| | - Arthur J Olch
- Radiation Oncology Program, Children's Hospital Los Angeles/Keck School of Medicine of the University of Southern California, Los Angeles, California
| |
Collapse
|
11
|
Vazquez T, Diaz D, Kodali N, Patel J, Keyes E, Sprow G, Sharma M, Ogawa-Momohara M, Grinnell M, Dan J, Werth V. 066 Plasmacytoid dendritic cells are not major producers of type 1 interferons in cutaneous lupus. J Invest Dermatol 2022. [DOI: 10.1016/j.jid.2022.05.120] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
12
|
Dan J, Sprow G, Afarideh M, Concha J, Kodali N, Vazquez T, Diaz D, Werth V. 223 Evaluation of nailfold capillaries in dermatomyositis using a dermatoscope. J Invest Dermatol 2022. [DOI: 10.1016/j.jid.2022.05.230] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
13
|
Ogawa-Momohara M, Li Y, Kodali N, Dan J, Vazquez T, Diaz D, Sprow G, Werth V. 041 Specific extracellular vesicles correlate with skin activity in dermatomyositis. J Invest Dermatol 2022. [DOI: 10.1016/j.jid.2022.05.095] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
14
|
Dan J, Concha J, Sprow G, Feng R, Afarideh M, Kodali N, Vazquez T, Diaz D, White B, Werth V. 238 Cutaneous dermatomyositis area and severity index activity score (CDASI-A) and associated patient-reported outcomes in a phase 2 clinical trial in dermatomyositis. J Invest Dermatol 2022. [DOI: 10.1016/j.jid.2022.05.245] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
15
|
Dan J, Afarideh M, Sprow G, Concha J, Kodali N, Vazquez T, Diaz D, Werth V. 239 Incidence and severity of itch and pain in bullous pemphigoid. J Invest Dermatol 2022. [DOI: 10.1016/j.jid.2022.05.246] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
16
|
Vazquez T, Sharma M, Feng R, Diaz D, Kodali N, Dan J, Grinnell M, Keyes E, Sprow G, White B, Werth V. 068 Lenabasum reduces IFNγ and pIRF3 in dermatomyositis skin: Biomarker results from a double-blind phase 3 international randomized controlled trial. J Invest Dermatol 2022. [DOI: 10.1016/j.jid.2022.05.122] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
17
|
Diaz D, Vazquez T, Kodali N, Grinnell M, Keyes E, Dan J, Sprow G, Li Y, Bashir M, Sharma M, Momohara M, Werth V. 023 Lenabasum, a cannabinoid type 2 receptor agonist, exerts anti-inflammatory effects in dermatomyositis in Th1 cells. J Invest Dermatol 2022. [DOI: 10.1016/j.jid.2022.05.077] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
18
|
Sprow G, Afarideh M, Dan J, Hedberg ML, Werth VP. Bullous systemic lupus erythematosus in females. Int J Womens Dermatol 2022; 8:e034. [PMID: 35923586 PMCID: PMC9324630 DOI: 10.1097/jw9.0000000000000034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2022] [Accepted: 06/06/2022] [Indexed: 11/30/2022] Open
Abstract
Bullous systemic lupus erythematosus (BSLE) is a rare blistering presentation of systemic lupus erythematosus, typically affecting women with the highest incidence in those of African descent. The key pathogenic insult includes the formation of autoantibodies against type VII collagen, which weaken the basement membrane zone and lead to the formation of subepidermal blisters. The acute vesiculobullous eruptions in BSLE generally tend to affect photo-distributed areas, although they can arise unrelated to sun exposure (eg, mucous membranes, axillae). The bullae can arise from erythematous macules, inflammatory plaques, or previously normal skin. Their appearance can range from small, grouped vesicles reminiscent of lesions in dermatitis herpetiformis to large, tense blisters, similar to bullous pemphigoid. Internal organ involvement occurs in up to 90% of those affected. This mostly includes lupus nephritis (classes III–V, lifetime prevalence of up to 90%), arthralgias/arthritis, and cytopenias, while serositis and neuropsychiatric involvement are rare. First-line management with dapsone should be considered in mild disease with stable underlying systemic lupus erythematosus. As discussed in this review, the off-label use of rituximab (an anti-CD20 B-cell depleting agent) has been shown to be safe and effective in several refractory cases of BSLE unresponsive to dapsone, glucocorticoids, or steroid-sparing immunosuppressants.
Collapse
|
19
|
Sprow G, Dan J, Merola JF, Werth VP. Emerging Therapies in Cutaneous Lupus Erythematosus. Front Med (Lausanne) 2022; 9:968323. [PMID: 35899214 PMCID: PMC9313535 DOI: 10.3389/fmed.2022.968323] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2022] [Accepted: 06/22/2022] [Indexed: 11/13/2022] Open
Abstract
Cutaneous lupus erythematosus (CLE) is an autoimmune disease that can occur with or without underlying systemic lupus erythematosus (SLE) and often has a profoundly negative impact on patient quality of life. There is substantial need for new and more effective therapies to treat CLE. CLE has a multifactorial pathogenesis that involves several key immune cells and pathways, including abnormalities in innate (e.g., type 1 interferon pathways) and adaptive immune responses (e.g., B and T cell autoreactivity), presenting multiple opportunities for more targeted therapies that do not require immunosuppression. Here we review several emerging therapies and their efficacy in CLE. Anifrolumab and belimumab have both been approved for the treatment of SLE in recent years, and clinical trial evidence suggests some forms of CLE may improve with these agents. Therapies currently in development that are being evaluated with CLE-specific outcome measures include BIIB059 and VIB7734, which target plasmacytoid dendritic cells (pDCs), and iberdomide, a cereblon modulator. These novel therapies all have previously demonstrated clinical benefit in some forms of CLE. Other therapies which target molecules believed to play a role in CLE pathogenesis, such as Janus kinases (JAKs), spleen tyrosine kinase (SYK), interferon γ (IFNγ), IL-12, and IL-23, have been evaluated in lupus clinical trials with skin-specific outcomes but failed to meet their primary endpoints.
Collapse
Affiliation(s)
- Grant Sprow
- Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States
- Dermatology, Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, United States
| | - Joshua Dan
- Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States
- Dermatology, Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, United States
| | - Joseph F. Merola
- Department of Dermatology, Department of Medicine, Division of Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States
| | - Victoria P. Werth
- Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States
- Dermatology, Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, United States
- *Correspondence: Victoria P. Werth
| |
Collapse
|
20
|
Dan J, Patel J, Sprow G, Concha J, Feng R, Kodali N, Vazquez T, Diaz D, White B, Werth V. AB1485 PATIENT-REPORTED OUTCOMES AND BIOMARKERS ASSOCIATED WITH THE CUTANEOUS DERMATOMYOSITIS AREA AND SEVERITY ACTIVITY (CDASI-A) SCORE IN A PHASE 2 CLINICAL TRIAL IN DERMATOMYOSITIS. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.4986] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundRetrospective reviews of clinical databases from two sites have identified strong relationships between patient-reported outcomes and skin activity in dermatomyositis (DM), as measured by CDASI-A.1,2 No studies validate these associations in a controlled setting. Additionally, the relationship between the PROMIS-29 Short Form and skin activity in DM has not been assessed. Previous investigations have demonstrated a correlation between IL-31 and itch in DM.3 IFN-β and IFN-γ are known type I and II interferons, which are critical drivers of DM pathogenesis.4ObjectivesTo assess correlations between CDASI-A, quality of life (QoL), and biomarkers of disease activity in a double-blind, randomized, placebo-controlled clinical trial.MethodsData were retrospectively collected from five visits of a Phase 2 trial evaluating Lenabasum, a cannabinoid receptor type 2 agonist. Quality of life assessments extracted from the trial included Patient Global Assessment (PtGA) scores, PROMIS domains, and Skindex domains. Skindex question 10, regarding itch, was included in the analysis as a separate domain. Physician Global Assessment scores were also evaluated. Additionally, biomarkers derived from skin samples via IHC/PCR collected at visits 1 and 6 were assessed for predictors of CDASI-A response and association with disease activity. Analysis used linear mixed effect models to account for within subject-variability and repeated measures, where applicable. Analysis was performed without regard to treatment arm, as our goal was to correlate CDASI, QoL, and biomarkers among all subjects.ResultsData from 22 subjects with DM and a combined total of 110 visits were included. Biopsies were collected from 12 subjects. Improvement in CDASI-A significantly correlated with Skindex-S, Skindex-E, Skindex-F, Skindex-Itch, PtGA global skin, PtGA global skin, PtGA global skin, and PtGA global skin, with p < 0.001. Improvement in PROMIS social role (p = 0.046) correlated with improvement in CDASI-A. Worsening of PROMIS fatigue (p = 0.019) and pain (p < 0.001) correlated with improvement in CDASI-A. Decreases in PGA overall disease, PGA skin activity, and PGA global skin all correlated with improvement of CDASI-A (p < 0.001). Change in IL-31 protein area positively correlated with change in disease activity (p = 0.047). A positive relationship between changes in IFN-β and IFN-γ protein area and disease activity trended towards significance.ConclusionIn accordance with previous investigations from our group, well-established measures of QoL correlated significantly with CDASI-A. These findings support that CDASI-A reflects both clinical and patient-reported aspects of skin disease and is an appropriate outcome in DM clinical trials. Additionally, Skindex and PtGA scores may better relate to skin activity as measured by the CDASI compared to PROMIS domains. IL-31, a cytokine previously associated with itch in DM,3 correlated significantly with CDASI-A in our study. Trends for IFN-β and IFN-γ reduction with disease improvement support their role in the pathogenesis of DM. This study helps define patient-reported outcomes and biomarkers that may be informative in DM trials.References[1]Goreshi R, et al. J Am Acad Dermatol. 2011;65(6):1107-1116[2]Robinson ES, et al. Br J Dermatol. 2015;172(1):169-174.[3]Patel J, et al. J Invest Dermatol. 2021;141(9):2151-2160.[4]Wong D, et al. PLoS One. 2012;7(1):e29161Disclosure of InterestsJoshua Dan: None declared, Jay Patel: None declared, Grant Sprow: None declared, Josef Concha: None declared, Rui Feng: None declared, Nilesh Kodali: None declared, Thomas Vazquez: None declared, DeAnna Diaz: None declared, Barbara White Shareholder of: Corbus Pharmaceuticals, Victoria Werth Speakers bureau: University of Pennsylvania, which owns the copyright for the CDASI, Grant/research support from: Corbus Pharmaceuticals
Collapse
|
21
|
Sprow G, Afarideh M, Dan J, Feng R, Keyes E, Grinnell M, Concha J, Werth VP. Autoimmune Skin Disease Exacerbations Following COVID-19 Vaccination. Front Immunol 2022; 13:899526. [PMID: 35693768 PMCID: PMC9186119 DOI: 10.3389/fimmu.2022.899526] [Citation(s) in RCA: 12] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2022] [Accepted: 04/20/2022] [Indexed: 11/17/2022] Open
Abstract
Background Vaccination against COVID-19 reduces the risk of severe COVID-19 disease and death. However, few studies have examined the safety of the COVID-19 vaccine in patients with autoimmune skin disease. Objectives We sought to determine the incidence of disease exacerbation in this population following COVID-19 vaccination as well as the associated factors. Methods We performed a chart review of all patients seen in the autoimmune skin disease clinic of the principal investigator during the study period. All patients included for analysis were systematically and prospectively asked about COVID-19 vaccination status, manufacturers, vaccine dates, autoimmune symptoms after the vaccine, and timing of symptom onset using a standardized template as part of their visit. Demographics and autoimmune disease diagnosis were also collected. Analysis used Chi-square and Fisher's exact tests. Results 402 subjects were included for analysis. 85.6% of patients were fully vaccinated, with 12.9% unvaccinated and 1.5% partially vaccinated. 14.8% of fully vaccinated patients reported worsening autoimmune signs and symptoms after the vaccine. Fully vaccinated dermatomyositis patients were more likely to report worsening autoimmune signs and symptoms after the vaccine (22.7%) than fully vaccinated lupus erythematosus patients (8.6%) (p=0.009). Patients fully vaccinated with the Moderna vaccine trended towards an increased likelihood of reporting worsening autoimmune signs and symptoms after the vaccine (19.1%) than those with the Pfizer-BioNTech vaccine (12.0%) (p=0.076). Of the patients who had autoimmune symptoms after vaccination, 20% had symptoms after the 1st dose, 82% after the 2nd dose, and 4% after the 3rd dose with median onset (95% confidence interval) of 7 (2,14), 14 (14,21), and 18 (7,28) days later, respectively. Conclusions More fully vaccinated dermatomyositis patients had exacerbation of autoimmune signs and symptoms after the vaccine than fully vaccinated lupus erythematosus patients. However, given the risks of COVID-19, clinicians should still promote vaccination in most patients with autoimmune skin disease.
Collapse
Affiliation(s)
- Grant Sprow
- Dermatology, Corporal Michael J. Crescenz Department of Veterans Affairs Medical Center, Philadelphia, PA, United States
- Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States
| | - Mohsen Afarideh
- Dermatology, Corporal Michael J. Crescenz Department of Veterans Affairs Medical Center, Philadelphia, PA, United States
- Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States
| | - Joshua Dan
- Dermatology, Corporal Michael J. Crescenz Department of Veterans Affairs Medical Center, Philadelphia, PA, United States
- Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States
| | - Rui Feng
- Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, PA, United States
| | - Emily Keyes
- Dermatology, Corporal Michael J. Crescenz Department of Veterans Affairs Medical Center, Philadelphia, PA, United States
- Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States
| | - Madison Grinnell
- Dermatology, Corporal Michael J. Crescenz Department of Veterans Affairs Medical Center, Philadelphia, PA, United States
- Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States
| | - Josef Concha
- Dermatology, Corporal Michael J. Crescenz Department of Veterans Affairs Medical Center, Philadelphia, PA, United States
- Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States
| | - Victoria P. Werth
- Dermatology, Corporal Michael J. Crescenz Department of Veterans Affairs Medical Center, Philadelphia, PA, United States
- Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States
| |
Collapse
|
22
|
Patel J, Vazquez T, Chin F, Keyes E, Yan D, Diaz D, Grinnell M, Sharma M, Li Y, Feng R, Sprow G, Dan J, Werth VP. Multidimensional immune profiling of cutaneous lupus erythematosus in vivo stratified by patient responses to antimalarials. Arthritis Rheumatol 2022; 74:1687-1698. [PMID: 35583812 DOI: 10.1002/art.42235] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2021] [Revised: 03/14/2022] [Accepted: 05/12/2022] [Indexed: 11/06/2022]
Abstract
OBJECTIVE The pathogenesis of cutaneous lupus erythematous (CLE) is multifactorial and CLE is difficult to treat due to heterogeneity of inflammatory processes between patients. Antimalarials such as hydroxychloroquine (HCQ) and quinacrine (QC) have long been first-line systemic therapy; however, many patients do not respond and require systemic immunosuppressants with undesirable side effects. Given the complexity and unpredictable responses in CLE, we sought to identify the immunologic landscape of CLE patients stratified by subsequent treatment outcomes to identify potential biomarkers of inducible response. METHOD We performed imaging mass cytometry with 48 treatment-naïve skin biopsies of HCQ responders, QC responders, and non-responders (NR) to analyze multiple immune cell types and inflammatory markers in their native environment in CLE skin. Patients were stratified according to their subsequent response to antimalarials to identify baseline immunophenotypes which may predict response to therapy. RESULTS HCQ responders demonstrated increased CD4 T cells compared to QC. NR had decreased Tregs compared to QC and increased central memory T cells compared to HCQ. QC responders expressed increased phosphorylated (p) STING and IFNκ compared to HCQ. pSTING and IFNκ localized to conventional dendritic cells and positively correlated on a tissue and cellular level. Neighborhood analysis revealed decreased regulatory cell interactions in NR patients. Hierarchical clustering revealed NR groups separated based on pSTAT2/3/4/5, pIRF3, Granzyme B, pJAK2, IL4, IL17, and IFNγ. CONCLUSION These findings demonstrate differential immune compositions between CLE patients, guiding the future for precision-based medicine and treatment response.
Collapse
Affiliation(s)
- Jay Patel
- Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, PA, 19104.,Department of Dermatology, School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | - Thomas Vazquez
- Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, PA, 19104
| | - Felix Chin
- Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, PA, 19104.,Department of Dermatology, School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | - Emily Keyes
- Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, PA, 19104.,Department of Dermatology, School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | - Daisy Yan
- Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, PA, 19104.,Department of Dermatology, School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | - DeAnna Diaz
- Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, PA, 19104.,Department of Dermatology, School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | - Madison Grinnell
- Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, PA, 19104.,Department of Dermatology, School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | - Meena Sharma
- Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, PA, 19104.,Department of Dermatology, School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | - Yubin Li
- Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, PA, 19104.,Department of Dermatology, School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | - Rui Feng
- Department of Biostatistics and Epidemiology, School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | - Grant Sprow
- Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, PA, 19104.,Department of Dermatology, School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | - Josh Dan
- Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, PA, 19104.,Department of Dermatology, School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | - Victoria P Werth
- Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, PA, 19104.,Department of Dermatology, School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
| |
Collapse
|
23
|
Affiliation(s)
- Grant Sprow
- Corporal Michael J. Crescenz Veterans Affairs Medical Center, Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania
- Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
| | - Joshua Dan
- Corporal Michael J. Crescenz Veterans Affairs Medical Center, Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania
- Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
| | - James Abbott
- Corporal Michael J. Crescenz Veterans Affairs Medical Center, Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania
- Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
| | - Angela Jiang
- Corporal Michael J. Crescenz Veterans Affairs Medical Center, Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania
- Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
| | - DeAnna Diaz
- Corporal Michael J. Crescenz Veterans Affairs Medical Center, Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania
- Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
| | - Thomas Vazquez
- Corporal Michael J. Crescenz Veterans Affairs Medical Center, Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania
- Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
| | - Nilesh Kodali
- Corporal Michael J. Crescenz Veterans Affairs Medical Center, Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania
- Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
| | - Victoria P. Werth
- Corporal Michael J. Crescenz Veterans Affairs Medical Center, Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania
- Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
- Correspondence to: Victoria P. Werth, MD, Department of Dermatology, Perelman Center for Advanced Medicine, University of Pennsylvania, Suite 1-330A, 3400 Civic Center Boulevard, Philadelphia, PA 19104.
| |
Collapse
|
24
|
Sprow G, Afarideh M, Werth VP. Interventions for Cutaneous Disease in Systemic Lupus Erythematosus: Summary of a Cochrane Review. JAMA Dermatol 2022; 158:200-201. [PMID: 35019939 DOI: 10.1001/jamadermatol.2021.5485] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
Clinical Question What is the efficacy of interventions for cutaneous disease in systemic lupus erythematosus (SLE) in randomized clinical trials (RCTs)? Bottom Line Available RCT evidence on the management of cutaneous disease in SLE is sparse and of limited quality. Among traditional options, methotrexate and hydroxychloroquine have the strongest evidence compared with placebo in the end points of complete clinical response and number of clinical flares, respectively, while chloroquine appears noninferior to methotrexate in achieving complete clinical response.
Collapse
Affiliation(s)
- Grant Sprow
- Corporal Michael J. Crescenz Veterans Affairs Medical Center, Department of Dermatology, University of Pennsylvania, Philadelphia.,Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia
| | - Mohsen Afarideh
- Corporal Michael J. Crescenz Veterans Affairs Medical Center, Department of Dermatology, University of Pennsylvania, Philadelphia.,Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia
| | - Victoria P Werth
- Corporal Michael J. Crescenz Veterans Affairs Medical Center, Department of Dermatology, University of Pennsylvania, Philadelphia.,Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia
| |
Collapse
|
25
|
Low JM, Lee NJ, Sprow G, Chlebik A, Olch A, Darrow K, Bowlin K, Wong KK. Scalp and Cranium Radiation Therapy Using Modulation (SCRUM) and Bolus. Adv Radiat Oncol 2020; 5:936-942. [PMID: 33083656 PMCID: PMC7557138 DOI: 10.1016/j.adro.2020.03.017] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2019] [Revised: 01/31/2020] [Accepted: 03/09/2020] [Indexed: 11/30/2022] Open
Abstract
Purpose A bolus is usually required to ensure radiation dose coverage of extensive superficial tumors of the scalp or skull. Oftentimes, these boluses are challenging to make and are nonreproducible, so an easier method was sought. Methods and Materials Thermoplastic sheets are widely available in radiation oncology clinics and can serve as bolus. Two template cutouts were designed for anterior and posterior halves to encompass the cranium of children and adults. Results The created bolus was imaged using computed tomography, which demonstrated good conformity and minimal air gaps. Conclusions Although making a bolus for treating superficial tumors of the scalp or head and neck is challenging, the presented technique enables thermoplastic to be used as a bolus and is quick, easy, and reproducible.
Collapse
Affiliation(s)
- Justin M. Low
- Long School of Medicine, University of Texas Health Science Center San Antonio, San Antonio, Texas
| | - Nicole J.H. Lee
- Touro University California College of Osteopathic Medicine, Vallejo, California
| | - Grant Sprow
- Albert Einstein College of Medicine, Bronx, New York
| | - Alisha Chlebik
- Children’s Center for Cancer and Blood Diseases, Children’s Hospital Los Angeles, Los Angeles, California
| | - Arthur Olch
- Children’s Center for Cancer and Blood Diseases, Children’s Hospital Los Angeles, Los Angeles, California
- Department of Radiation Oncology, Keck School of Medicine of the University of Southern California, Los Angeles, California
| | - Kaleb Darrow
- University of Tennessee Health Science Center College of Medicine, Memphis, Tennessee
| | - Kristine Bowlin
- Children’s Center for Cancer and Blood Diseases, Children’s Hospital Los Angeles, Los Angeles, California
| | - Kenneth K. Wong
- Children’s Center for Cancer and Blood Diseases, Children’s Hospital Los Angeles, Los Angeles, California
- Department of Radiation Oncology, Keck School of Medicine of the University of Southern California, Los Angeles, California
- Corresponding author: Kenneth K. Wong, MD
| |
Collapse
|